SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
____________________________________
Date of report (Date of earliest event reported): June 30,
1998
CARDIAC SCIENCE, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 0-19567
33-0465681
(State or Other Juris- (Commission File
No.) (IRS Employer
diction of Incorporation)
Identification No.)
1176 Main Street, Suite C, Irvine, CA
92614
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
(714) 587-0357
(Former Name or Former Address, if Changed Since
Last Report.)
ITEM 9. Sales of Equity Securities Pursuant to
Regulation S.
On June 30, 1998, Cardiac Science, Inc. (the
"Corporation") sold 200,000 shares of the Corporation's
common stock, par value $0.001 per share (the "Common
Stock"), at $2.00 per share, to a foreign investor in an
offshore transaction pursuant to Regulation S promulgated
under the Securities Act of 1933, as amended. In
connection with the offering, the Corporation is obligated
to pay a finders fee equal to ten percent of the gross
proceeds of the sale, payable in cash or Common Stock.
<PAGE>
Signatures
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned
thereunto duly authorized.
CARDIAC SCIENCE, INC.
By:/s/ Raymond W. Cohen
Raymond W. Cohen, President and Chief Executive
Officer
Date: July 1, 1998
